A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

Case Medical Research ◽

10.31525/ct1-nct03980002 ◽

2019 ◽

Author(s):

Keyword(s):

Phase 2 ◽

Multicenter Phase ◽

Phase 2 Study ◽

Treatment Naïve

Download Full-text

Rg-101 in Combination With 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High Virologic Response Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multicenter, Phase 2 Study

Journal of Hepatology ◽

10.1016/s0168-8278(16)01665-2 ◽

2016 ◽

Vol 64 (2) ◽

pp. S159 ◽

Author(s):

G. Horvath ◽

G. Papatheodoridis ◽

M. Fabri ◽

M. Makara ◽

P. Grint ◽

...

Keyword(s):

Chronic Hepatitis ◽

Virologic Response ◽

Phase 2 ◽

Direct Acting Antiviral ◽

Multicenter Phase ◽

Phase 2 Study ◽

Treatment Naïve ◽

Direct Acting ◽

Chronic Hepatitis C Patients

Download Full-text

15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208

Digestive and Liver Disease ◽

10.1016/s1590-8658(10)60385-4 ◽

2010 ◽

Vol 42 ◽

pp. S6-S7 ◽

Author(s):

M. Colombo ◽

M.G. Rumi ◽

G. Carosi ◽

M. Puoti ◽

P. Marcellin ◽

...

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Multicenter Phase ◽

Phase 2 Study ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718390800.793495363 ◽

2014 ◽

Author(s):

James Bussel

Keyword(s):

Immune Thrombocytopenic Purpura ◽

Phase 2 ◽

Efficacy And Safety ◽

Thrombocytopenic Purpura ◽

Chronic Immune Thrombocytopenic Purpura ◽

Multicenter Phase ◽

Download Full-text

Faculty Opinions recommendation of A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725819857.793510074 ◽

2015 ◽

Author(s):

Marilyn Telen

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Adult Patients ◽

Phase 2 ◽

Cell Disease ◽

Double Blind ◽

Multicenter Phase ◽

Download Full-text

P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers

Annals of Oncology ◽

10.1016/j.annonc.2021.05.150 ◽

2021 ◽

Vol 32 ◽

pp. S130

Author(s):

K. Muro ◽

J. Bruce ◽

J. Baranda ◽

S. Gorla ◽

C. Wu ◽

...

Keyword(s):

Solid Tumors ◽

Locally Advanced ◽

Phase 2 ◽

Gastrointestinal Cancers ◽

Multicenter Phase ◽

Phase 2 Study ◽

Previously Treated ◽

Upper Gastrointestinal

Download Full-text

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Cancer ◽

10.1002/cncr.29864 ◽

2016 ◽

Vol 122 (9) ◽

pp. 1434-1443 ◽

Author(s):

Didier Meulendijks ◽

Jan Willem B. de Groot ◽

Maartje Los ◽

James E. Boers ◽

Laurens V. Beerepoot ◽

...

Keyword(s):

Gastric Cancer ◽

Line Treatment ◽

Phase 2 ◽

Multicenter Phase ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

Poster: MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01477-4 ◽

2021 ◽

Vol 21 ◽

pp. S234

Author(s):

Vikas Gupta ◽

Marina Kremyanskaya ◽

John Mascarenhas ◽

Francesca Palandri ◽

Andrea Patriarca ◽

...

Keyword(s):

Subgroup Analysis ◽

Clinical Benefit ◽

Jak Inhibitor ◽

Phase 2 ◽

Phase 2 Study ◽

Treatment Naïve ◽

Inhibitor Treatment

Download Full-text

Pembrolizumab in mycosis fungoides and Sézary syndrome: Updated results of the CITN multicenter Phase 2 study

European Journal of Cancer ◽

10.1016/j.ejca.2018.07.304 ◽

2018 ◽

Vol 101 ◽

pp. S37 ◽

Author(s):

Michael S. Khodadoust ◽

Alain H. Rook ◽

Pierluigi Porcu ◽

Francine Foss ◽

Alison Moskowitz ◽

...

Keyword(s):

Mycosis Fungoides ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Phase 2 ◽

Multicenter Phase ◽

Download Full-text

P-273 Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study

Annals of Oncology ◽

10.1093/annonc/mdw199.263 ◽

2016 ◽

Vol 27 ◽

pp. ii79

Author(s):

Satake Hironaga ◽

Tsuji Akihito ◽

Hashida Hiroki ◽

Tanioka Hiroaki ◽

Miyake Yasuhiro ◽

...

Keyword(s):

Colorectal Cancer ◽

Adjuvant Chemotherapy ◽

Liver Metastases ◽

Phase 2 ◽

Multicenter Phase ◽

Download Full-text

Abstract P5-18-16: A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER2-Positive Metastatic Breast Cancer

10.1158/0008-5472.sabcs12-p5-18-16 ◽

2012 ◽

Author(s):

N Masuda ◽

Y Ito ◽

S Takao ◽

H Doihara ◽

Y Rai ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Japanese Patients ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Efficacy And Safety ◽

Her2 Positive ◽

Multicenter Phase ◽

Phase 2 Study ◽

Heavily Pretreated

Download Full-text